RVNC’s CEO said on today’s Barclays webcast that RVNC has not seen any impact from COVID-19 on its clinical trials. Several of RVNC’s clinical trials, including the phase-3 ASPEN-1 study in CD, have enrolled and treated all patients and are now in observation mode.
The CEO also said that RVNC has hired most of its regional sales managers and that the Teoxane launch is still scheduled for 2Q20.
There is also no change in the 11/25/20 PDUFA date for RVNC's Daxi BLA in glabellar lines.
News 
Market Data 
Discover 
